874 related articles for article (PubMed ID: 8453674)
1. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
2. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
Pope BL; Chourmouzis E; Victorino L; MacIntyre JP; Capetola RJ; Lau CY
J Immunol; 1993 Sep; 151(6):3007-17. PubMed ID: 8376766
[TBL] [Abstract][Full Text] [Related]
3. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines.
Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG
Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754
[TBL] [Abstract][Full Text] [Related]
4. The immunostimulatory compound 7-allyl-8-oxoguanosine (loxoribine) induces a distinct subset of murine cytokines.
Pope BL; MacIntyre JP; Kimball E; Lee S; Zhou L; Taylor GR; Goodman MG
Cell Immunol; 1995 May; 162(2):333-9. PubMed ID: 7743561
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
6. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine: I. Activation of natural killer cells in mice.
Sharma BS; Mhaskar S; Balazs L; Siaw M
Immunopharmacol Immunotoxicol; 1992; 14(1-2):1-19. PubMed ID: 1597650
[TBL] [Abstract][Full Text] [Related]
8. Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of Candida albicans cell wall.
Scaringi L; Cornacchione P; Rosati E; Fettucciari K; Rossi R; Marconi P
Cell Immunol; 1994 May; 155(2):265-82. PubMed ID: 8181065
[TBL] [Abstract][Full Text] [Related]
9. The NK1.1 antigen in NK-mediated F1 antiparent killing in vitro.
Kung SK; Miller RG
J Immunol; 1995 Feb; 154(4):1624-33. PubMed ID: 7836747
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.
Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S
Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134
[TBL] [Abstract][Full Text] [Related]
12. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset.
Ballas ZK; Rasmussen W
J Immunol; 1993 Jan; 150(1):17-30. PubMed ID: 7678028
[TBL] [Abstract][Full Text] [Related]
14. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
15. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer (LAK) cells. V. 8-Mercaptoguanosine as an IL-2-sparing agent in LAK generation.
Thompson RA; Ballas ZK
J Immunol; 1990 Nov; 145(10):3524-31. PubMed ID: 1700014
[TBL] [Abstract][Full Text] [Related]
17. Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells.
Dobashi H; Seki S; Habu Y; Ohkawa T; Takeshita S; Hiraide H; Sekine I
Hepatology; 1999 Aug; 30(2):430-6. PubMed ID: 10421651
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses.
Wang M; Ellison CA; Gartner JG; HayGlass KT
J Immunol; 1998 Feb; 160(3):1098-105. PubMed ID: 9570522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
